UK markets close in 7 hours 17 minutes
  • FTSE 100

    7,088.39
    +44.36 (+0.63%)
     
  • FTSE 250

    22,853.65
    +315.76 (+1.40%)
     
  • AIM

    1,188.79
    +7.17 (+0.61%)
     
  • GBP/EUR

    1.1835
    +0.0059 (+0.50%)
     
  • GBP/USD

    1.3351
    +0.0012 (+0.09%)
     
  • BTC-GBP

    43,004.46
    +2,048.88 (+5.00%)
     
  • CMC Crypto 200

    1,433.70
    -21.71 (-1.49%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • DOW

    34,899.34
    -905.06 (-2.53%)
     
  • CRUDE OIL

    71.24
    +3.09 (+4.53%)
     
  • GOLD FUTURES

    1,800.40
    +12.30 (+0.69%)
     
  • NIKKEI 225

    28,283.92
    -467.70 (-1.63%)
     
  • HANG SENG

    23,852.24
    -228.28 (-0.95%)
     
  • DAX

    15,285.60
    +28.56 (+0.19%)
     
  • CAC 40

    6,762.92
    +23.19 (+0.34%)
     

Relief Reports U.S. Collaboration Partner has Announced Favorable New Safety Report for Aviptadil in NIH Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

  • Oops!
    Something went wrong.
    Please try again later.
·3-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RELIEF THERAPEUTICS Holding AG / Key word(s): Study results

03-Nov-2021 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

Relief Reports that its U.S. Collaboration Partner has Announced a Favorable, New Safety Report for Aviptadil in the National Institutes of Health Sponsored ACTIV-3b Critical Care Study in Patients with Life-Threatening COVID-19

Geneva, Switzerland, November 3, 2021 - RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF) ("Relief"), a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported today that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx"), has issued a press release announcing a new safety update on aviptadil, which is being tested in the ACTIV-3b Critical Care Phase 3 study sponsored by the National Institutes of Health. According to the press release, in its third scheduled analysis, the study's Independent Data Safety Monitoring Board found no new safety concerns after reviewing a total of more than 300 patients and recommended continued enrollment to target 640 patients. The related NRx press release can be accessed through the following link.

ABOUT RELIEF

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief's lead drug candidate, RLF-100(TM) (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. As part of its pipeline diversification strategy, in March 2021, Relief entered into a Collaboration and License Agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001. ACER-001 is a taste-masked and immediate release proprietary powder formulation of sodium phenylbutyrate (NaPB) for the treatment of Urea Cycle Disorders and Maple Syrup Urine Disease. In addition, Relief's recently completed acquisitions of APR Applied Pharma Research SA and AdVita Lifescience GmbH, bring to Relief a diverse pipeline of marketed and development-stage programs.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbol RLFTF. For more information, visit www.relieftherapeutics.com. Follow us on LinkedIn.

CONTACT:
RELIEF THERAPEUTICS Holding SA

Jack Weinstein
Chief Financial Officer and Treasurer
contact@relieftherapeutics.com


FOR MEDIA/INVESTOR INQUIRIES:
Rx Communications Group

Michael Miller
+1-917-633-6086
mmiller@rxir.com

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve certain known and unknown risks, uncertainties and other factors, including (i) whether aviptadil will ever be approved in the U.S., the U.K., or the E.U. for the treatment of respiratory failure in patients with COVID-19, and (ii) those risks discussed in RELIEF THERAPEUTICS Holding SA's press releases and filings with the SIX, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


End of ad hoc announcement

Language:

English

Company:

RELIEF THERAPEUTICS Holding AG

Avenue de Sécheron 15

1202 Genève

Switzerland

E-mail:

contact@relieftherapeutics.com

Internet:

https://relieftherapeutics.com

ISIN:

CH0100191136

Listed:

SIX Swiss Exchange

EQS News ID:

1245631


 

End of Announcement

EQS Group News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting